New York, NY (PRWEB) July 27, 2012
Medmeme, LLC., as a global leader in comprehensive, integrated medical and science information database platforms, has released the new syndicated TrendsmemeTM Report: Metabolic Disorders. Its primary focus is on type 2 diabetes, metabolic syndrome, and obesity. These disorders are often interlinked and also lead to development, or exacerbation, of other diseases such as cardiovascular disease and cancer, subjects of other TrendsmemeTM reports. Obesity is present in 37.5% of U.S. adults - a 10% increase since 2008 - predisposing them to type 2 diabetes and metabolic syndrome. In 2011, 105 million people in the United States have either pre-diabetes or diabetes. Nearly 26 million Americans have type 2 diabetes, and about 27% of this population is unaware that they have it. A factor that may forecast the future is highlighted by one other particular statistic. Seventeen percent of children and adolescents ages 2-19 years old are reported to be obese.
For the three indications - type 2 diabetes, metabolic syndrome, and obesity - the TrendsmemeTM Report gives details of the science and medical communities, and the pharmaceutical industry trends in disease understanding, treatment patterns, R&D, company strategy, unmet needs, and opportunities and challenges. Leading pharma companies involved in R&D and in the marketplace are: Eli Lilly, Merck, Novo Nordisk, Bristol-Myers Squibb, Takeda Pharmaceutical Company, Pfizer, Sanofi, GlaxoSmithKline, Amylin Pharmaceuticals, and Johnson & Johnson. Also active in the therapeutic category, among other companies, are: Arena Pharmaceuticals, Ember Therapeutics, Gelesis Pharmaceuticals, Orexigen, Rhythm Pharmaceuticals, Vivus, and Zafgen.
A trend detailed in the report is partnering in the R&D pipeline to bring innovative new treatments to the market. Examples include Eli Lilly with Boehringer Ingelheim (SGLT-2 inhibitors and insulin analogs), Novo Nordisk with Merrion and Emisphere (GLP-1 and insulin analogs with better drug absorption in the gut), Bristol-Myers Squibb with AstraZeneca (SGLT-2 inhibitors and Kombiglyze, a drug combining Onglyza with metformin XR), and Arena Pharmaceuticals partner for US marketing of recently approved obesity drug Belviq is Eisai. Also, Amylin was acquired by Bristol-Myers Squibb based on diabetes drugs in Amylin’s pipeline, and AstraZeneca has a new diabetes drug marketing agreement with BMS.
Medmeme CEO Mahesh Naithani looks at the challenges: “Even when all the players are doing all that can be done to educate the public about obesity and diabetes, we still don’t know to what degree that will change outcomes in the future. Realizing something is going to take a certain number of years from a lifetime is difficult to think about. But another way to measure the consequences of these disorders is the tremendous cost for treatment, and loss of productivity. Recently John Cawley at Cornell University published a study that found obesity accounts for nearly 21% of U.S. health care spending, or $190.2 billion a year. Fortunately, the pharmaceutical industry has a significant pipeline of new treatments. And the broad coverage treatment approach in new drugs is a good thing too. At Medmeme our contribution to meeting the challenge presented by metabolic disorders is to provide our clients the best, up-to-date, accurate, insightful, data and analysis to help them in all phases of their efforts to bring control to this extremely serious health care threat; their efforts from discovery to drug launch.”
The syndicated TrendsmemeTM Report: Metabolic Disorders can be purchased separately, or, along with other MedMeme reports in the new series, at discounted pricing. To learn more, contact us, or see our website, http://www.medmeme.com/products/syndicated-reports/reports/trendsmeme-reports
Yan Barshay, Executive Vice President
Ray Wright, Vice President, Sales
+ 1 508-278-4595